Literature DB >> 30166022

Central Nervous System Pseudoprogression With Nivolumab in a Patient With Squamous Cell Lung Cancer Followed by Prolonged Response.

Umang Swami1, Mark Smith2, Jun Zhang3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30166022     DOI： 10.1016/j.jtho.2018.05.001

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  3 in total

1.  [A Case of Pseudoprogression During Atezolizumab Therapy 
in Lung Adenocarcinoma].

Authors:  Xue Wang; Yi Zhao; Zhiwei Chen
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2019-06-20

Review 2.  Immune response evaluation criteria in solid tumors for assessment of atypical responses after immunotherapy.

Authors:  Davide Ippolito; Cesare Maino; Maria Ragusi; Marco Porta; Davide Gandola; Cammillo Talei Franzesi; Teresa Paola Giandola; Sandro Sironi
Journal:  World J Clin Oncol       Date:  2021-05-24

3.  The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy.

Authors:  Wenxiao Jia; Qianqian Gao; Anqin Han; Hui Zhu; Jinming Yu
Journal:  Cancer Biol Med       Date:  2019-11       Impact factor: 4.248
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.